title: Sublingual misoprostol after surgical management of early termination of pregnancy.
abstract: OBJECTIVE
  To assess the efficacy of sublingual misoprostol after surgical management of early termination of pregnancy (ETP) regarding duration and amount of bleeding, presence of retained products of conception (RPOC), and endometrial thickness.
  
  
  METHODS
  Prospective, randomized clinical trial.
  
  
  METHODS
  University hospital.
  
  
  METHODS
  One hundred five patients admitted for possible management of early pregnancy failure and unwanted pregnancy.
  
  
  METHODS
  Manual vacuum aspiration (control and study groups) plus 400 microg sublingual misoprostol (study group) at pregnancy termination, and transvaginal ultrasonography (both groups) 10 days after the procedure.
  
  
  METHODS
  Duration and amount of bleeding and presence of RPOC and endometrial thickness 10 days after the procedure.
  
  
  RESULTS
  Bleeding lasted 3.2 and 5.1 days in the study and control groups. Severe vaginal bleeding occurred in two patients in the study group and in six patients in the control group. Mean endometrial thickness was 5.5 mm in the study group and 6.9 mm in the control group. These differences were statistically significant. No cases of RPOC occurred in the study group; two cases occurred in the control group.
  
  
  CONCLUSIONS
  In countries in which surgical management of ETP is still done, using sublingual misoprostol postoperatively may reduce the duration and amount of bleeding.
authors.affiliation: Department of Obstetrics and Gynecology, Alanya, Turkey. brsmlym@yahoo.com
authors.forename: Baris
authors.initials: B
authors.lastname: Mulayim
authors.forename: Nilufer Y
authors.initials: NY
authors.lastname: Celik
authors.forename: Gogsen
authors.initials: G
authors.lastname: Onalan
authors.forename: Hulusi B
authors.initials: HB
authors.lastname: Zeyneloglu
authors.forename: Esra
authors.initials: E
authors.lastname: Kuscu
mesh_terms: D000020:Abortifacient Agents, Nonsteroidal / Q000008:administration & dosage; D000028:Abortion, Induced / Q000009:adverse effects*; D000286:Administration, Sublingual; D000328:Adult; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D016595:Misoprostol / Q000008:administration & dosage*; D019106:Postoperative Hemorrhage / Q000517:prevention & control*; D016896:Treatment Outcome; D014619:Vacuum Curettage / Q000009:adverse effects*
chemical_list: D000020:Abortifacient Agents, Nonsteroidal; D016595:Misoprostol